## Review setup

- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the supplied abstract text
- **Shared manuscript claim summary** The authors report a computational analysis of the first class of potent small molecules disrupting the YAP-TEAD protein-protein interaction. They claim that pharmacophore analysis augmented by solvation analysis of molecular dynamics trajectories can guide design, that binding free energy calculations provide insight into binding conformation and energetics, that computed binding free energy estimates agree with experimental findings, and that their results provide rationale for structure-based design efforts leading to significant potency gains.
- **Visible evidence base** Abstract text only. No figures, tables, methods, or supporting information were provided.
- **Missing materials affecting confidence** Full manuscript text, all figures and tables, computational methods details, force field parameters, simulation protocols, error estimates for binding free energies, experimental data referenced for comparison, and any statistical analyses. Without these, quantitative claims cannot be independently assessed.

## Reviewer

- **Overall assessment** The abstract presents a potentially useful computational framework for analyzing ligand binding to a challenging protein-protein interaction surface. The topic is timely and the target is of therapeutic relevance. However, the abstract provides insufficient methodological detail and no quantitative results to support the central claims. The statement that computed binding free energies agree with experimental findings is unverifiable from the supplied material. The work may be of interest to computational chemists and drug discovery researchers, but the case for its conclusions is not established from the abstract alone.
- **Who would be interested in the results, and why** Computational chemists and structure-based drug designers working on protein-protein interaction targets would be interested in the methodological approach combining pharmacophore analysis, molecular dynamics, and binding free energy calculations. Researchers in the YAP-TEAD oncology field would also be interested in the structural insights into this specific interaction. The work could inform future small molecule discovery efforts for shallow or flat binding interfaces.
- **Major strengths** The target is clinically relevant and the challenge of drugging a flat protein-protein interface is well recognized. The abstract explicitly connects the work to a previously reported experimental discovery, providing context. The proposed combination of pharmacophore analysis with solvation analysis from molecular dynamics is a reasonable and potentially valuable methodological angle. The authors acknowledge the difficulty of the shallow binding site, which frames the work appropriately.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria** Originality: The combination of pharmacophore and solvation analysis for this specific target appears novel, but the abstract does not clearly differentiate the approach from standard computational workflows. Scientific importance: The target is important, but the abstract does not demonstrate that the findings advance understanding beyond the cited experimental work. Interdisciplinary readership: The abstract is written for a specialist computational audience and would not be accessible to a broad readership. Technical soundness: Cannot be assessed from the abstract alone. Readability for nonspecialists: The abstract uses field-specific terminology without sufficient context, limiting accessibility.
- **Recommendation posture** Currently not established from the provided evidence. The abstract suggests potentially interesting work, but the absence of quantitative results and methodological detail prevents any assessment of validity. A full manuscript with detailed methods and results would be required to evaluate the claims.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The authors claim that computed binding free energy estimates agree with experimental findings.
- **Evidence pointer** Abstract text, location not provided
- **Concern** The abstract states that binding free energy calculations agree with experimental findings but provides no numerical values, no comparison metrics, no error estimates, and no specification of which experimental data were used. No figure or table is referenced.
- **Why it matters** This is the central quantitative claim of the work. Without any data showing the comparison, the claim is unverifiable and cannot be evaluated for accuracy or significance.
- **Resolution test** Provide a table or figure showing computed versus experimental binding free energies for all compounds studied, including statistical uncertainties and the source of experimental values.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Methodological transparency
- **Claim pointer** The authors claim that pharmacophore analysis augmented by solvation analysis of molecular dynamics trajectories can guide design.
- **Evidence pointer** Abstract text, location not provided
- **Concern** No methodological details are provided for the pharmacophore construction, the molecular dynamics simulation protocol, the solvation analysis, or the binding free energy method. The abstract does not state which software, force field, simulation length, or analysis approach was used.
- **Why it matters** Reproducibility is a fundamental requirement for computational studies. Without these details, the methods cannot be replicated or assessed for appropriateness, and the claim that the approach "can guide design" is unsupported.
- **Resolution test** Include a methods section describing all computational protocols in sufficient detail for reproduction, including software versions, force fields, simulation parameters, and analysis procedures.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Claim substantiation
- **Claim pointer** The authors claim that their results provide rationale for structure-based design efforts that led to significant potency gains.
- **Evidence pointer** Abstract text, location not provided
- **Concern** The abstract does not present any structural or energetic data linking specific pharmacophore features or binding conformations to the potency gains reported in the cited experimental work. No compounds are named, no structures are shown, and no quantitative structure-activity relationships are described.
- **Why it matters** This claim implies that the computational analysis explains experimental observations. Without a direct and explicit connection between the computational results and the experimental potency data, the claim is speculative.
- **Resolution test** Present a detailed comparison between the computational predictions and the experimental potency data for the compound series, including structural overlays or energy decomposition analyses that identify the specific determinants of potency.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract background statement
- **Evidence pointer** Abstract text, location not provided
- **Issue** The abstract states the YAP-TEAD interface is approximately 3500 square angstroms but does not specify the units in the text as written. The value appears without a unit label in the supplied text.
- **Required correction** Specify the units explicitly as square angstroms or square nanometers.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Terminology
- **Affected element** Abstract phrase "hot-spot derived from their previously rationally designed peptidic inhibitor"
- **Evidence pointer** Abstract text, location not provided
- **Issue** The term "hot-spot" is used without definition or context. It is unclear whether this refers to a computational hot-spot prediction, an experimental alanine scanning result, or a structural definition.
- **Required correction** Define what is meant by hot-spot in this context and how it was derived.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Referencing
- **Affected element** Abstract statement about the cited experimental work
- **Evidence pointer** Abstract text, location not provided
- **Issue** The abstract references the work by Furet and coworkers with a DOI but does not clearly distinguish which specific findings from that work are being used as the basis for the current analysis.
- **Required correction** Clarify which specific compounds, data, or structural information from the cited work are used in the present study.

## Risk / unsupported claims

- The claim that computed binding free energy estimates agree with experimental findings is unsupported because no quantitative comparison is provided.
- The claim that pharmacophore analysis augmented by solvation analysis can guide design is unassessable without methodological details.
- The claim that the results provide rationale for potency gains is unsupported because no direct link between computational results and experimental potency data is shown.
- The general statement that the approach could enable small molecule discovery for such targets is speculative and not substantiated by the abstract.